KRAS and non-small cell lung carcinoma: Notably, ERBB2 mutations in NSCLC are typically mutually exclusive of other driver mutations, such as EGFR, KRAS, and ALK rearrangements, highlighting their potential to serve as distinct therapeutic targets [19].